Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 399 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Testosterone Clear all

Conditions: Female Sexual Dysfunction, Anorgasmia
Interventions: Not listed
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections, Cachexia
Interventions: testosterone; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 3
States / cities: Los Angeles, California • Torrance, California • St Louis, Missouri

Conditions: Klinefelter Syndrome
Interventions: testosterone cypionate 200mg/ml; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 42 Days to 108 Days · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypoactive Sexual Desire Disorder
Interventions: testosterone gel, placebo gel; Drug
Lead sponsor: BioSante Pharmaceuticals; Industry
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 60
States / cities: Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 56 more

Conditions: Overweight and Obesity, Hyperandrogenemia, Insulin Resistance
Interventions: Mediterranean-based, carbohydrate restricted, calorie reduced diet; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Priapism, Sickle Cell Disease, Hypogonadism
Interventions: Transdermal Androgel; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer, Castration-resistant, Metastatic
Interventions: testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypogonadism
Interventions: QuickShot™ - 50 mg Treatment B, QuickShot™ - 100 mg Treatment A, Delatestryl 200 mg IM Treatment C; Drug
Lead sponsor: Antares Pharma Inc.; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Brookline, Massachusetts

Conditions: Hypogonadism
Interventions: testosterone matrix transdermal system; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Fort Meyers, Florida • Tacoma, Washington

Conditions: Hypogonadism, Male
Interventions: Testosterone Undecanoate; Drug
Lead sponsor: Clarus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Northbrook, Illinois

Conditions: Female Orgasmic Disorder
Interventions: Placebo, Low dose TBS-2, Medium dose TBS-2, High dose TBS-2; Drug
Lead sponsor: Acerus Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 37 more

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Small Cell Carcinoma
Interventions: Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 2
States / cities: Detroit, Michigan • Houston, Texas

Conditions: Rotator Cuff Tear
Interventions: Oxandrolone, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 40 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Biopsy of Prostate, Biospecimen Collection, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Therapeutic Testosterone; Procedure · Other · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hypogonadism, Male
Interventions: Testosterone enanthate; Combination Product
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 12 Years to 17 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 22
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 18 more

Conditions: Smoking
Interventions: Not listed
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Enzalutamide, Rucaparib camsylate, Placebo, Leuprolide Acetate, Goserelin Acetate, Degarelix, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 414
States / cities: Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 298 more

Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin Acetate, Histrelin Acetate, Leuprolide Acetate, Nilutamide, Orchiectomy, Prednisone, Quality-of-Life Assessment, Radiation Therapy, Radical Prostatectomy, Triptorelin; Drug · Procedure · Other + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2036
U.S. locations: 334
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 253 more

Conditions: Hypogonadism
Interventions: ARD-0403; Drug
Lead sponsor: Ardana Bioscience Ltd; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 12
States / cities: Huntsville, Alabama • Stanford, California • Torrance, California + 9 more

Conditions: Prostate Cancer
Interventions: DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Enzalutamide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Autonomic Neuropathy, Male Hypogonadism
Interventions: Not listed
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 40 Years to 80 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Prostatic Hyperplasia
Interventions: Dutasteride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 11
States / cities: Long Beach, California • New Britain, Connecticut • Trumbull, Connecticut + 8 more

Conditions: Hypogonadism, Male
Interventions: NatestoTM; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hypoactive Sexual Desire Disorder
Interventions: testosterone gel, placebo gel; Drug
Lead sponsor: BioSante Pharmaceuticals; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 3,656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 141
States / cities: Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 116 more

Search by objective public record fields.

Clitoral Location in Relation to Sexual Function Using Pelvic Imaging

Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women

Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment

Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

Evaluating the Influence of Diet-induced Weight Loss on Fat (Adipose) Tissue's Insulin Sensitivity and Testosterone Synthesis in Women With Overweight or Obesity, Insulin Resistance, and Hyperandrogenemia

Androgen Regulation of Priapism in Sickle Cell Disease

Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer

Pharmacokinetic Study of Testosterone Enanthate

Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems

Assessment of Blood From Men Receiving Oral TU in Various Collection Tubes

Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder

Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer

Oxandrolone Rotator Cuff Trial

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

Maternal Smoking During Pregnancy and Female Fetal Testosterone Levels

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Open-Label Study of ARD-0403 in Testosterone Deficient Men

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Autonomic Manifestations of Testosterone Deficiency in Men

Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels

Natesto Spermatogenesis Reboot

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women